Allogene Therapeutics, Inc. Common Stock (ALLO) is a publicly traded Healthcare sector company. As of May 21, 2026, ALLO trades at $1.92 with a market cap of $669.60M and a P/E ratio of -2.17. ALLO moved +0.53% today. Year to date, ALLO is +40.74%; over the trailing twelve months it is +63.79%. Its 52-week range spans $0.86 to $4.46. Analyst consensus is strong buy with an average price target of $8.71. Rallies surfaces ALLO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ALLO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.92 |
| Market Cap | $669.60M |
| P/E Ratio | -2.17 |
| EPS | $-0.87 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.46 |
| 52-Week Low | $0.86 |
| Volume | 4.28K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-190.89M |
| Gross Margin | 0.00% |
14 analysts cover ALLO: 0 strong buy, 12 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.71.